Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007

Radiotherapy and Oncology

Volumn 91, Issue 1, 2009, Pages 85-94

  MacManus, Michael ^a,b   Nestle, Ursula ^c   Rosenzweig, Kenneth E ^d   Carrio, Ignasi ^e   Messa, Cristina ^f,g   Belohlavek, Otakar ^h   Danna, Massimo ⁱ   Inoue, Tomio ^j   Deniaud Alexandre, Elizabeth ^k   Schipani, Stefano ⁱ   Watanabe, Naoyuki ^l   Dondi, Maurizio ^l   Jeremic, Branislav ^l  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SAARLAND UNIVERSITY   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^h NA HOMOLCE HOSPITAL   (Czech Republic)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j YOKOHAMA CITY UNIVERSITY   (Japan)

^k HÔPITAL TENON   (France)

^l INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

more..

Author keywords

Chemotherapy; Computed tomography; Positron Emission Tomography; Radiation therapy; Treatment planning

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICAL EXPERT; MEDICAL SOCIETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 62549156647     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.11.008     Document Type: Review

References (145)

1. Hawkins R.A., and Hoh C.K. PET FDG studies in oncology. Nucl Med Biol 21 (1994) 739-747
2. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 (2000) 551-560
3. Dogan N., Leybovich L.B., Sethi A., and Emami B. Improvement of dose distributions in abutment regions of intensity modulated radiation therapy and electron fields. Med Phys 29 (2002) 38-44
4. Zelefsky M.J., Leibel S.A., Kutcher G.J., and Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand?. Semin Radiat Oncol 8 (1998) 107-114
5. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
6. Seute T., Leffers P., ten Velde G.P., and Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 112 (2008) 1827-1834
7. Van de Steene J., Linthout N., de Mey J., et al. Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol 62 (2002) 37-49
8. van Herk M., Remeijer P., and Lebesque J.V. Inclusion of geometric uncertainties in treatment plan evaluation. Int J Radiat Oncol Biol Phys 52 (2002) 1407-1422
9. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
10. Baum R.P., Hellwig D., and Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 48 (2004) 119-142
11. Weber W.A., and Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33 Suppl. 1 (2006) 27-37
12. Ling C.C., and Li X.A. Over the next decade the success of radiation treatment planning will be judged by the immediate biological response of tumor cells rather than by surrogate measures such as dose maximization and uniformity. Med Phys 32 (2005) 2189-2192
13. Zasadny K.R., Kison P.V., Francis I.R., and Wahl R.L. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging 1 (1998) 123-129
14. Miles K.A., Griffiths M.R., and Keith C.J. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 33 (2006) 22-28
15. Marom E.M., Aloia T.A., Moore M.B., et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33 (2001) 99-107
16. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15 (2001) 471-486
17. Schoder H., Larson S.M., and Yeung H.W. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45 Suppl. 1 (2004) 72S-81S
18. Miyazawa H., Arai T., Iio M., and Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 34 (1993) 1886-1891
19. Geets X., Daisne J.F., Gregoire V., Hamoir M., and Lonneux M. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 71 (2004) 267-273
20. Kubota K., Ishiwata K., Kubota R., et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, l-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32 (1991) 2118-2123
21. Inoue T., Koyama K., Oriuchi N., et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study. Radiology 220 (2001) 54-62
22. Langen K.J., Hamacher K., Weckesser M., et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33 (2006) 287-294
23. Grosu A.L., Weber W.A., Riedel E., et al. l-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 64-74
24. Reske S.N., Blumstein N.M., Neumaier B., et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47 (2006) 1249-1254
25. Heinisch M., Dirisamer A., Loidl W., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?. Mol Imaging Biol 8 (2006) 43-48
26. Yamaguchi T., Lee J., Uemura H., et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32 (2005) 742-748
27. Ciernik I.F., Brown D.W., Schmid D., Hany T., Egli P., and Davis J.B. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat 6 (2007) 23-30
28. Yoshida S., Nakagomi K., Goto S., Futatsubashi M., and Torizuka T. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int 74 (2005) 214-220
29. Rajendran J.G., and Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 43 (2005) 169-187
30. Schwaiger M., and Peschel C. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. Eur J Nucl Med Mol Imaging 33 Suppl. 1 (2006) 1-5
31. Thorwarth D., Eschmann S.M., Scheiderbauer J., Paulsen F., and Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5 (2005) 152
32. Thorwarth D., Eschmann S.M., Paulsen F., and Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 50 (2005) 2209-2224
33. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance. Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
34. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
35. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 (2005) 945-952
36. Paulino A.C., and Johnstone P.A. FDG-PET in radiotherapy treatment planning: Pandora's box?. Int J Radiat Oncol Biol Phys 59 (2004) 4-5
37. Lucignani G., Jereczek-Fossa B.A., and Orecchia R. The role of molecular imaging in precision radiation therapy for target definition, treatment planning optimisation and quality control. Eur J Nucl Med Mol Imaging 31 (2004) 1059-1063
38. Mutic S., Dempsey J.F., Bosch W.R., et al. Multimodality image registration quality assurance for conformal three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 51 (2001) 255-260
39. van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 14 (2004) 52-64
40. Westerterp M., Pruim J., Oyen W., et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34 (2007) 392-404
41. Grgic A, Nestle U, Schaefer-Schuler A, Kremp S, Kirsch C, Hellwig D. FDG-PET-BASED radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning - an intraindividual comparison. Int J Radiat Oncol Biol Phys, 2008.
42. Slomka P.J., Dey D., Przetak C., Aladl U.E., and Baum R.P. Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT. J Nucl Med 44 (2003) 1156-1167
43. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1016-1023
44. Caldwell C.B., Mah K., Skinner M., and Danjoux C.E. Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET. Int J Radiat Oncol Biol Phys 55 (2003) 1381-1393
45. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
46. Leong T., Everitt C., Yuen K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 78 (2006) 254-261
47. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
48. Pötzsch C., Hofheinz F., and van den Hoff J. Vergleich der Inter-Observer-Variabilität bei manueller und automatischer Volumenbestimmung in der PET. Nuklearmedizin 45 (2006) A42
49. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., and Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33 (1992) 1972-1980
50. Ryu J.S., Choi N.C., Fischman A.J., Lynch T.J., and Mathisen D.J. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35 (2002) 179-187
51. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 60 (2004) 1272-1282
52. Hong R., Halama J., Bova D., Sethi A., and Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 67 (2007) 720-726
53. Bayne M., MacManus M., Hicks R., Leong T., Peters L., and Ball D. Can a mathematical formula help define a radiation target volume using positron emission tomography? In regard to Black et al. (Int J Radiat Oncol Biol Phys 2004;60:1272-82). Int J Radiat Oncol Biol Phys 62 (2005) 299-300 [author reply 300]
54. Yaremko B., Riauka T., Robinson D., et al. Thresholding in PET images of static and moving targets. Phys Med Biol 50 (2005) 5969-5982
55. Yaremko B., Riauka T., Robinson D., Murray B., McEwan A., and Roa W. Threshold modification for tumour imaging in non-small-cell lung cancer using positron emission tomography. Nucl Med Commun 26 (2005) 433-440
56. Lodge M.A., Badawi R.D., Gilbert R., Dibos P.E., and Line B.R. Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner. J Nucl Med 47 (2006) 23-31
57. Daisne J.F., Sibomana M., Bol A., Doumont T., Lonneux M., and Gregoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 69 (2003) 247-250
58. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80 Suppl. 12 (1997) 2505-2509
59. Geets X., Lee J.A., Bol A., Lonneux M., and Gregoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 34 (2007) 1427-1438
60. Daisne J.F., Duprez T., Weynand B., et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
61. Nestle U., Schaefer-Schuler A., Kremp S., et al. Target volume definition for (18)F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 453-462
62. van Baardwijk A., Bosmans G., Boersma L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68 (2007) 771-778
63. Keall P.J., Joshi S., Vedam S.S., Siebers J.V., Kini V.R., and Mohan R. Four-dimensional radiotherapy planning for DMLC-based respiratory motion tracking. Med Phys 32 (2005) 942-951
64. Remouchamps V.M., Vicini F.A., Sharpe M.B., Kestin L.L., Martinez A.A., and Wong J.W. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 55 (2003) 392-406
65. Webb S. Motion effects in (intensity modulated) radiation therapy: a review. Phys Med Biol 51 (2006) R403-R425
66. Nehmeh S.A., Erdi Y.E., Pan T., et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys 31 (2004) 1333-1338
67. Shimizu S., Shirato H., Ogura S., et al. Detection of lung tumor movement in real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 304-310
68. Vansteenkiste J., Fischer B.M., Dooms C., and Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5 (2004) 531-540
69. Mac Manus M.P., Wong K., Hicks R.J., Matthews J.P., Wirth A., and Ball D.L. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52 (2002) 351-361
70. Mac Manus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92 (2001) 886-895
71. Messa C., Di Muzio N., Picchio M., Gilardi M.C., Bettinardi V., and Fazio F. PET/CT and radiotherapy. Q J Nucl Med Mol Imaging 50 (2006) 4-14
72. Deniaud-Alexandre E., Touboul E., Lerouge D., et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1432-1441
73. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
74. Dwamena B.A., Sonnad S.S., Angobaldo J.O., and Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213 (1999) 530-536
75. Hellwig D., Groschel A., Rentz K., Sybrecht G.W., Kirsch C.M., and Ukena D. Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose. Pneumologie 55 (2001) 363-366
76. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., and Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 42 Suppl. 5 (2001) 1S-93S
77. Graeter T.P., Hellwig D., Hoffmann K., Ukena D., Kirsch C.M., and Schafers H.J. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75 (2003) 231-235 [discussion 235-6]
78. Hellwig D., Ukena D., Paulsen F., Bamberg M., and Kirsch C.M. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 55 (2001) 367-377
79. Schmücking M., Baum R.P., Bonnet R., Junker K., and Muller K.M. Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 26 (2005) 178-189
80. Reske S.N., and Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 28 (2001) 1707-1723
81. Mac Manus M.P., Hicks R.J., Matthews J.P., McKenzie A., Rischin D., Salminen E.K., et al. Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy/chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
82. Mac Manus M.P., Hicks R.J., Matthews J.P., Wirth A., Rischin D., and Ball D.L. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49 (2005) 95-108
83. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 (2004) 412-418
84. Mac Manus M.P., and Hicks R.J. Impact of PET on radiation therapy planning in lung cancer. Radiol Clin North Am 45 (2007) 627-638
85. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
86. Rosenzweig K.E., Sura S., Jackson A., and Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25 (2007) 5557-5561
87. Zhao L., Chen M., Ten Haken R., et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82 (2007) 153-159
88. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert no-elective into elective nodal irradiation (ENI)?. Radiother Oncol 71 (2004) 123-125
89. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
90. Hellwig D., Gröschel A., Rentz K., Sybrecht G.W., Kirsch C.M., and Ukena D. Aussagekraft der Positronen-Emissions-Tomographie mit F-18-Fluordesoxyglukose (FDG-PET) beim Bronchioloalveolarzellkarzinom (BAC). Pneumologie 55 (2001) 363-366
91. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
92. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30 (2007) 239-244
93. Jeremic B. Low incidence of isolated nodal failures after involved-field radiation therapy for non small-cell lung cancer: blinded by the light?. J Clin Oncol 25 (2007) 5543-5545
94. Schumacher T., Brink I., Mix M., et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 28 (2001) 483-488
95. Bradley J.D., Dehdashti F., Mintun M.A., Govindan R., Trinkaus K., and Siegel B.A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (2004) 3248-3254
96. Blum R., Mac Manus M.P., Rischin D., Michael M., Ball D., and Hicks R.J. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 27 (2004) 164-171
97. Pandit N., Gonen M., Krug L., and Larson S.M. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 30 (2003) 78-84
98. Kamel E.M., Zwahlen D., Wyss M.T., Stumpe K.D., von Schulthess G.K., and Steinert H.C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
99. Chin Jr. R., McCain T.W., Miller A.A., et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37 (2002) 1-6
100. Wang D., Schultz C.J., Jursinic P.A., et al. Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 143-151
101. Scarfone C., Lavely W.C., Cmelak A.J., et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 45 (2004) 543-552
102. Schwartz D.L., Ford E., Rajendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 129-136
103. Paulino A.C., Koshy M., Howell R., Schuster D., and Davis L.W. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1385-1392
104. Riegel A.C., Berson A.M., Destian S., et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 65 (2006) 726-732
105. Breen S.L., Publicover J., De Silva S., et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys 68 (2007) 763-770
106. Nowak B., Di Martino E., Janicke S., et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 38 (1999) 312-318
107. Dietl B., Marienhagen J., Kuhnel T., Schaefer C., and Kolbl O. FDG-PET in radiotherapy treatment planning of advanced head and neck cancer - a prospective clinical analysis. Auris Nasus Larynx 33 (2006) 303-309
108. Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 73 (2004) 261-263
109. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33 (1995) 391-398
110. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
111. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850
112. Eschmann S.M., Paulsen F., Reimold M., et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46 (2005) 253-260
113. Blum R.H., Seymour J.F., Wirth A., MacManus M., and Hicks R.J. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4 (2003) 43-49
114. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 66 Suppl. (2005) 90-97
115. Wirth A., Seymour J.F., Hicks R.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112 (2002) 262-268
116. Divgi C. Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol 32 Suppl. 1 (2005) S11-S18
117. Mikhaeel N.G. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 33 Suppl. 13 (2006) 22-26
118. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52 (2004) 19-32
119. Hutchings M., Loft A., Hansen M., Berthelsen A.K., and Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78 (2007) 206-212
120. Spaepen K., Stroobants S., Verhoef G., and Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 30 Suppl. 1 (2003) S97-S105
121. Haioun C., Itti E., Rahmouni A., et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
122. Mikhaeel N.G., Hutchings M., Fields P.A., O'Doherty M.J., and Timothy A.R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
123. Kostakoglu L., Coleman M., Leonard J.P., Kuji I., Zoe H., and Goldsmith S.J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43 (2002) 1018-1027
124. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
125. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., and Timothy A.R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 (2005) 1160-1168
126. Duong C.P., Demitriou H., Weih L., et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 33 (2006) 759-769
127. Choi J.Y., Lee K.H., Shim Y.M., et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 41 (2000) 808-815
128. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
129. Vrieze O., Haustermans K., De Wever W., et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 73 (2004) 269-275
130. Moureau-Zabotto L., Touboul E., Lerouge D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 340-345
131. Lin L.L., Mutic S., Malyapa R.S., et al. Sequential FDG-PET brachytherapy treatment planning in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 63 (2005) 1494-1501
132. Schiepers C. PET/CT in colorectal cancer. J Nucl Med 44 (2003) 1804-1805
133. Vasanawala M.S., Wang Y., Quon A., and Gambhir S.S. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med 31 (2006) 534-537
134. Schwimmer J., Essner R., Patel A., et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 44 (2000) 153-167
135. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
136. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23 (1999) 105-114
137. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
138. Giraud P., De Rycke Y., Minet P., et al. Estimation of the probability of mediastinal involvement: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy in non-small-cell lung cancer?. Cancer Radiother 5 (2001) 725-736
139. Mah K., Caldwell C.B., Ung Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 339-350
140. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
141. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
142. Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53 (2002) 1051-1057
143. Brianzoni E., Rossi G., Ancidei S., et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 32 (2005) 1392-1399
144. Messa C., Ceresoli G.L., Rizzo G., et al. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. Q J Nucl Med Mol Imaging 49 (2005) 259-266
145. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655